Benzinga | Jun 16, 2021 09:24AM EDT

Aegis Capital Downgrades Kindred Biosciences to Hold, Lowers Price Target to $9.25

Aegis Capital analyst Nathan Weinstein downgrades Kindred Biosciences (NASDAQ:KIN) from Buy to Hold and lowers the price target from $16 to $9.25.